{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:40:25Z","timestamp":1779219625965,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ijantimicag.2023.106968","type":"journal-article","created":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T21:38:42Z","timestamp":1694986722000},"page":"106968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-5673","authenticated-orcid":false,"given":"Sanjay","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1749-3705","authenticated-orcid":false,"given":"Gunavanthi D.","family":"Boorgula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prem","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3929-6369","authenticated-orcid":false,"given":"Tania A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keertan","family":"Dheda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesibana","family":"Malinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prithvi","family":"Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Aryal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8786-8851","authenticated-orcid":false,"given":"Shashikant","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106968_bib0001","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01786-2021","article-title":"Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study","volume":"58","author":"Migliori","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0002","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1056\/NEJMp2118145","article-title":"Covid-19\u2032s devastating effect on tuberculosis care - a path to recovery","volume":"386","author":"Pai","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0003","series-title":"Global Tuberculosis Report 2021","year":"2021"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0004","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/AAC.00106-09","article-title":"Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0005","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1128\/AAC.01418-13","article-title":"Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug","volume":"58","author":"McLeay","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0006","unstructured":"No_Author_Listed. SIVEXTRO (tedizolid phosphate). 2014."},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0007","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1183\/09031936.00191712","article-title":"Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence","volume":"42","author":"Sotgiu","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0008","doi-asserted-by":"crossref","first-page":"949","DOI":"10.5588\/ijtld.10.0616","article-title":"Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients","volume":"15","author":"Diacon","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0009","article-title":"Precision and Personalized Medicine and anti\u2013TB treatment: Is TDM feasible for programmatic use?","author":"Alffenaar","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0010","unstructured":"European Medicines Agencies. Qualification opinion on in vitro hollow fibre system model of tuberculosis (HFS-TB). 2015."},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0011","article-title":"Novel tuberculosis combination regimens of two and three-months therapy duration","author":"Gumbo","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00751-17","article-title":"Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis","volume":"61","author":"Srivastava","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0013","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/ciw482","article-title":"Linezolid for infants and toddlers with disseminated tuberculosis: first steps","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0014","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/cid\/ciw483","article-title":"Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: Goldilocks","volume":"63","author":"Srivastava","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0015","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2023.106968_bib0016","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1093\/cid\/civ426","article-title":"Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2023.106968_bib0017","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/cid\/civ425","article-title":"Systematic analysis of hollow fiber model of tuberculosis experiments","volume":"61","author":"Pasipanodya","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2023.106968_bib0018","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1093\/cid\/civ427","article-title":"Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0019","doi-asserted-by":"crossref","first-page":"e02232","DOI":"10.1128\/AAC.02232-17","article-title":"Antibacterial and sterilizing effect of benzylpenicillin in tuberculosis","volume":"62","author":"Deshpande","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0020","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/INF.0000000000002857","article-title":"Evaluation of ceftriaxone plus avibactam in an intracellular hollow fiber model of tuberculosis: Implications for the treatment of disseminated and meningeal tuberculosis in children","volume":"39","author":"Srivastava","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.677005","article-title":"Cefdinir and beta-lactamase Inhibitor Independent efficacy against Mycobacterium tuberculosis","volume":"12","author":"Srivastava","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.776969","article-title":"Repurposing cefazolin-avibactam for the treatment of drug resistant Mycobacterium tuberculosis","volume":"12","author":"Srivastava","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0023","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1701102","article-title":"Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis","volume":"3","author":"Deshpande","year":"2017","journal-title":"Sci Adv"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0024","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1128\/AAC.00320-06","article-title":"Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics","volume":"50","author":"Wang","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01489-18","article-title":"Evaluation of carbapenems for treatment of multi- and extensively drug-resistant Mycobacterium tuberculosis","volume":"63","author":"van Rijn","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0026","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1164\/rccm.202108-1976OC","article-title":"Early Bactericidal cctivity of meropenem plus clavulanate (with or without rifampin) for tuberculosis: The COMRADE randomized, phase 2A clinical trial","volume":"205","author":"De Jager","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0027","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1586\/eri.12.96","article-title":"Reappraising the use of \u03b2-lactams to treat tuberculosis","volume":"10","author":"Kurz","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0028","unstructured":"No_Author_Listed. VABOMERE\u2122 (meropenem and vaborbactam) for injection, for intravenous use. U.S.A. Food and Drug Administration; 2017."},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0029","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00284-006-0135-1","article-title":"Nucleotide polymorphism associated with ethambutol resistance in clinical isolates of Mycobacterium tuberculosis","volume":"53","author":"Srivastava","year":"2006","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0030","series-title":"CLSI Standard M24","article-title":"Susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes","year":"2018"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02039-16","article-title":"Sterilizing effect of ertapenem-clavulanate in a hollow-fiber model of tuberculosis and implications on clinical dosing","volume":"61","author":"van Rijn","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0032","series-title":"Rapid communication: Key changes to the treatment of drug-resistant tuberculosis (WHO\/UCN\/TB\/2022.2)","year":"2022"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0033","series-title":"Rapid communication: Key changes to the treatment of drug-resistant tuberculosis","year":"2022"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0034","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/infdis\/jir658","article-title":"Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability","volume":"204","author":"Srivastava","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0035","doi-asserted-by":"crossref","first-page":"S359","DOI":"10.1093\/cid\/ciy627","article-title":"Efficacy versus hepatotoxicity of high-dose rifampin, pyrazinamide, and moxifloxacin to shorten tuberculosis therapy duration: there is still fight in the old warriors yet!","volume":"67","author":"Srivastava","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0036","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ijid.2021.01.062","article-title":"Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration","volume":"104","author":"Gumbo","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0037","series-title":"Phoenix\u00ae WinNonlin\u00ae version 8.1","year":"2020"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2023.106968_bib0038","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/infdis\/jiu610","article-title":"Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia","volume":"211","author":"Gumbo","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0039","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12154-009-0029-3","article-title":"Hill coefficients, dose-response curves and allosteric mechanisms","volume":"3","author":"Prinz","year":"2010","journal-title":"J Chem Biol"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0041","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1128\/AAC.00753-16","article-title":"Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis","volume":"60","author":"Almeida","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0042","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01948-20","article-title":"Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis","volume":"65","author":"Rifat","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0043","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1093\/cid\/ciy608","article-title":"Pharmacokinetic\/pharmacodynamic background and methods and scientific evidence base for dosing of second-line tuberculosis drugs","volume":"67","author":"Gumbo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0044","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","article-title":"Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. A randomized controlled trial","volume":"198","author":"Velasquez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0045","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0046","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1093\/cid\/cir184","article-title":"Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?","volume":"52","author":"van Ingen","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0047","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1086\/651377","article-title":"Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol","volume":"201","author":"Srivastava","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0048","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1128\/AAC.00269-11","article-title":"Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling","volume":"55","author":"Srivastava","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0049","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.1128\/AAC.00829-13","article-title":"Thioridazine pharmacokinetic-pharmacodynamic parameters \u201cwobble\u201d during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners","volume":"57","author":"Musuka","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0050","article-title":"Drug concentration thresholds predictive of outcome in children with tuberculosis: not your parents' target concentrations","author":"Srivastava","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0052","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/cid\/ciw472","article-title":"A combination regimen design program based on pharmacodynamic target setting for childhood tuberculosis: Design rules for the playground","volume":"63","author":"Srivastava","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0053","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1128\/AAC.00961-16","article-title":"Amikacin optimal exposure targets in the hollow fiber system model of tuberculosis","volume":"60","author":"Srivastava","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0054","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ebiom.2016.02.040","article-title":"A long-term co-perfused disseminated tuberculosis-3D liver hollow fiber model for both drug efficacy and hepatotoxicity in babies","volume":"6","author":"Srivastava","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0055","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1093\/cid\/ciy626","article-title":"The sterilizing effect of intermittent tedizolid for pulmonary tuberculosis","volume":"67","author":"Srivastava","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106968_bib0056","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0962-8479(92)90145-A","article-title":"in vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule","volume":"73","author":"Watt","year":"1992","journal-title":"Tuber Lung Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T21:03:45Z","timestamp":1718658225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923002479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0924857923002479"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106968","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106968"}}